CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Hematologic Oncology Update
00:00
CAR T role in diffuse large B‑cell lymphoma
Jeremy recommends CAR T as second-line for most relapsed DLBCL, citing improved cure rates versus transplant.
Play episode from 13:41
Transcript
